NCT04760522 Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program
| NCT ID | NCT04760522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Rare Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2021-06-01 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12,000 participants in total. It began in 2021-06-01 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES). The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented. The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.
Eligibility Criteria
Inclusion Criteria: * Unclear molecular cause of the disease * Suspected genetic cause of the disease Exclusion Criteria: * Missing informed consent of the patient and if applicable the legal representative * Previously performed WES or panel analysis
Contact & Investigator
Olaf Rieß, Prof. Dr.
STUDY DIRECTOR
University Hospital Tübingen
Frequently Asked Questions
Who can join the NCT04760522 clinical trial?
This trial is open to participants of all sexes, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04760522 currently recruiting?
Yes, NCT04760522 is actively recruiting participants. Contact the research team at olaf.riess@med.uni-tuebingen.de for enrollment information.
Where is the NCT04760522 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT04760522 clinical trial?
NCT04760522 is sponsored by University Hospital Tuebingen. The principal investigator is Olaf Rieß, Prof. Dr. at University Hospital Tübingen. The trial plans to enroll 12,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.